Global Therapeutic Vaccines Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 198 pages | ID: GF97E1182FCEN
Precision Business Insights (PBI)

Abstracts

Global Therapeutic Vaccines Market:

Global therapeutic vaccines market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for therapeutic vaccines is projected to reach US$ XX Mn by 2023.

Therapeutic vaccines are biological combinations which develop immunity against a diseased tissue or cell. Therapeutic vaccines are administered to the patient in order to induce a defence mechanism against particular disease. These are developed to treat various cancer diseases, HIV, and Alzheimer’s disease etc. Prophylactic vaccines differ from therapeutic vaccines are used for the prevention and control of diseases, while the prophylactic vaccines are only used for prevention of diseases. Therapeutic vaccines are specially manufactured for the HIV positive individuals with the healthy immune system, to increase the ability to fight against microorganisms. Therapeutic vaccines are currently developed for chronic viral infections, such as human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), cancer, hepatitis B virus, and hepatitis C virus etc. as an alternative to antiviral treatment.

The global therapeutic vaccines market is expected to grow at a significant CAGR due to increase in the prevalence of chronic diseases such as cancer, and HIV etc. According to World Health Organisation, an escalation of the diseases such as cancer (approximately 8.8 Mn people died in 2015) and HIV expected to drive the growth of global therapeutic vaccines market over the forecasting period. The advanced and active R&D activities for therapeutic vaccines by pharmaceutical companies for various types of cancers are in pipeline which is expected to create potential opportunity in the global therapeutic vaccines market in future. Apart from this, rising number of mergers and acquisitions, and an increase in funding from government for development of therapeutic vaccines might fuel the growth of global therapeutic vaccines market over the forecasting period. However, inefficient research and development and non-existent reimbursement policies for vaccines are the primary factors which are expected to hinder the growth of global therapeutic vaccines market. Similarly, stringent regulatory implications, higher cost of vaccines, lesser accessibility to the vaccines, availability of alternative treatments for the diseases, and some adverse effects associated with the vaccines might hamper the growth of global therapeutic vaccines market over the forecast period.

Global therapeutic vaccines market has been segmented on the basis of product type, application, technologies, market type, and end user

Based on product type, global therapeutic vaccines market has been segmented into the following:

• Conjugate vaccines
• Live attenuated vaccines
• Inactivated and subunit vaccines
• Toxoid vaccines
• Recombinant vaccines

Based on application, global therapeutic vaccines market has been segmented into the following:

• Infectious Diseases
• Oncology
• Addiction
• Autoimmune diseases
• Neurological diseases
• Others

Based on technology, global therapeutic vaccines market has been segmented into the following:

• Autologous vaccines
• Allogeneic vaccines

Based on the valency, global therapeutic vaccines market has been segmented into the following:

• Monovalent vaccines
• Multivalent vaccines

Based on the end-user, global therapeutic vaccines market has been segmented into the following:

• Hospitals
• Clinic
• Others

The global therapeutic vaccines market is in the nascent stage where many players are actively involved in the development of therapeutic vaccines. Few companies have adopted some key business strategies, such as product innovation, and new product launching to ensure their dominance in the global therapeutic vaccines market. The global therapeutic vaccines market is positively affected by the significant rise in prevalence of chronic diseases such as cancer, and HIV etc. Few companies have taken an active lead in research and development of therapeutic vaccines. For instance, in April 2010, Dendreon Corporation, launched FDA approved immunotherapy drug Provenge, for the treatment of prostate cancer. According to U.S. Department of Health and Human Services, there are some vaccines in the clinical trial stage, such as Lucanix (Belagenpumatucel-L), gp100 melanoma vaccine, for Non-small cell lung cancer. Similarly, Merck & Co., Inc. and GSK Plc. are expected to launch vaccines such as GSK1572932A, and GV1001 having entered phase 3 trials.

Geographically, the global therapeutic vaccines market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts for the largest share in global therapeutic vaccines market followed by Europe and Asia-Pacific. In North-America, U.S. contributes the largest share in global therapeutic vaccines market (according to U.S. Centres for Disease Control and Prevention (CDC), therapeutic vaccines can suppress almost 10 infectious diseases in U.S. by up to 90%). Rising technology support for the development of new vaccines and well-developed healthcare infrastructure expected to fuel the growth of therapeutic vaccines market in North-America region. Europe, which currently stands at the second position in global therapeutic vaccines market, and is expected to show a significant growth due to the increase in the number of patients with chronic diseases. Asia-Pacific region expected to grow at a significant rate due to rising prevalence of various infectious and chronic diseases and aging population. Large investments in the field of research and development and increasing medical tourism in Asian countries might fuel the growth of therapeutic vaccine market in the Asia-pacific region. Latin America is another important regional market, which offers vast opportunities for the players entering into this market, and is expected to grow moderately due to the high cost of therapeutic vaccines.

Some of the players in global therapeutic vaccines market are Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi-Pasteur (France), Dendreon (U.S.). Agenus Inc. (U.S.), Valeant (Canada), Bavarian Nordic (Denmark), Pfizer, Inc. (U.S.) and Inovio Pharmaceuticals, Inc. (U.S.), to name a few.

In May 2017, Pfizer started phase 1 clinical trials on PF-06753512, a therapeutic vaccine for the treatment of prostate cancer

In December 2015, Bavarian collaborated and licensed with Janssen for MVA-BN in the development of a therapeutic HPV vaccine

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenari

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL THERAPEUTIC VACCINES MARKET INTRODUCTION

2.1. Global Therapeutic Vaccines Market– Taxonomy
2.2. Global Therapeutic Vaccines Market–Definitions
  2.2.1. Product Type
  2.2.2. Application

3. GLOBAL THERAPEUTIC VACCINES MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Therapeutic Vaccines Market Dynamics – Factors Impact Analysis
3.6. Global Therapeutic Vaccines Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan

4. GLOBAL THERAPEUTIC VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL THERAPEUTIC VACCINES MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Conjugate Vaccines
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Live attenuated Vaccines
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Inactivated and Subunit Vaccines
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Toxoid Vaccines
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Recombinant Vaccines
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis

6. GLOBAL THERAPEUTIC VACCINES MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Infectious Diseases
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Oncology
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Addiction
  6.3.1. Market Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Autoimmune Diseases
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Neurological Diseases
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis
6.6. Others
  6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.6.3. Market Opportunity Analysis

7. GLOBAL THERAPEUTIC VACCINES MARKET FORECAST, BY TECHNOLOGY, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Autologous Vaccines
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Allogeneic Vaccines
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis

8. GLOBAL THERAPEUTIC VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospitals
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Clinics
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Others
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis

9. GLOBAL THERAPEUTIC VACCINES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Therapeutic Vaccines Market- Opportunity Analysis Index - By Product Type, Application, By Technology, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA THERAPEUTIC VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Conjugate Vaccines
    10.1.1.2. Live Attenuated Vaccines
    10.1.1.3. Inactivated and Subunit Vaccines
    10.1.1.4. Toxoid Vaccines
    10.1.1.5. Recombinant Vaccines
  10.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Infectious Diseases
    10.1.2.2. Oncology
    10.1.2.3. Addiction
    10.1.2.4. Autoimmune Diseases
    10.1.2.5. Neurological Diseases
    10.1.2.6. Others
  10.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Autologous Vaccines
    10.1.3.2. Allogeneic Vaccines
  10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Hospitals
    10.1.4.2. Clinics
    10.1.4.3. Others
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Therapeutic Vaccines Market- Opportunity Analysis Index - By Product Type, By Application, By Technology, By Distribution Channel, and Country, 2017 – 2023
  10.1.7. North America Therapeutic Vaccines Market Dynamics – Trends

11. EUROPE THERAPEUTIC VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Conjugate Vaccines
    11.1.1.2. Live Attenuated Vaccines
    11.1.1.3. Inactivated and Subunit Vaccines
    11.1.1.4. Toxoid Vaccines
    11.1.1.5. Recombinant Vaccines
  11.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Infectious Diseases
    11.1.2.2. Oncology
    11.1.2.3. Addiction
    11.1.2.4. Autoimmune Diseases
    11.1.2.5. Neurological Diseases
    11.1.2.6. Others
  11.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Autologous Vaccines
    11.1.3.2. Allogeneic Vaccines
  11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Hospitals
    11.1.4.2. Clinics
    11.1.4.3. Others
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Therapeutic Vaccines Market- Opportunity Analysis Index - By Product Type, By Application, By Technology, By Distribution Channel, and Country, 2017 – 2023
  11.1.7. Europe Therapeutic Vaccines Market Dynamics – Trends

12. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Conjugate Vaccines
    12.1.1.2. Live Attenuated Vaccines
    12.1.1.3. Inactivated and Subunit Vaccines
    12.1.1.4. Toxoid Vaccines
    12.1.1.5. Recombinant Vaccines
  12.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Infectious Diseases
    12.1.2.2. Oncology
    12.1.2.3. Addiction
    12.1.2.4. Autoimmune Diseases
    12.1.2.5. Neurological Diseases
    12.1.2.6. Others
  12.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Autologous Vaccines
    12.1.3.2. Allogeneic Vaccines
  12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Hospitals
    12.1.4.2. Clinics
    12.1.4.3. Others
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Therapeutic Vaccines Market- Opportunity Analysis Index - By Product Type, By Application, By Technology, By Distribution Channel, and Country, 2017 – 2023
  12.1.7. Asia-Pacific Therapeutic Vaccines Market Dynamics – Trends

13. LATIN AMERICA THERAPEUTIC VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Conjugate Vaccines
    13.1.1.2. Live Attenuated Vaccines
    13.1.1.3. Inactivated and Subunit Vaccines
    13.1.1.4. Toxoid Vaccines
    13.1.1.5. Recombinant Vaccines
  13.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Infectious Diseases
    13.1.2.2. Oncology
    13.1.2.3. Addiction
    13.1.2.4. Autoimmune Diseases
    13.1.2.5. Neurological Diseases
    13.1.2.6. Others
  13.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Autologous Vaccines
    13.1.3.2. Allogeneic Vaccines
  13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Hospitals
    13.1.4.2. Clinics
    13.1.4.3. Others
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Therapeutic Vaccines Market- Opportunity Analysis Index - By Product Type, By Application, By Technology, By Distribution Channel, and Country, 2017 – 2023
  13.1.7. Latin America Therapeutic Vaccines Market Dynamics – Trends

14. MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.1.1. Conjugate Vaccines
    14.1.1.2. Live Attenuated Vaccines
    14.1.1.3. Inactivated and Subunit Vaccines
    14.1.1.4. Toxoid Vaccines
    14.1.1.5. Recombinant Vaccines
  14.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Infectious Diseases
    14.1.2.2. Oncology
    14.1.2.3. Addiction
    14.1.2.4. Autoimmune Diseases
    14.1.2.5. Neurological Diseases
    14.1.2.6. Others
  14.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Autologous Vaccines
    14.1.3.2. Allogeneic Vaccines
  14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Hospitals
    14.1.4.2. Clinics
    14.1.4.3. Others
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Therapeutic Vaccines Market- Opportunity Analysis Index - By Product Type, By Application, By Technology, By Distribution Channel, and Country, 2017 – 2023
  14.1.7. MEA Therapeutic Vaccines Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Merck & Co., Inc. (U.S.)
  15.2.2. GlaxoSmithKline plc (U.K.)
  15.2.3. Novartis AG (Switzerland)
  15.2.4. Sanofi-Pasteur (France)
  15.2.5. Dendreon (U.S.)
  15.2.6. Agenus Inc. (U.S.)
  15.2.7. Valeant (Canada)
  15.2.8. Bavarian Nordic (Denmark)
  15.2.9. Pfizer, Inc. (U.S.)
  15.2.10. Inovio Pharmaceuticals, Inc. (U.S.)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS